Intelsius, a DGP company, a designer, manufacturer, and distributor of temperature-controlled packaging solutions, based in York, UK, has enjoyed two successful attendances at leading London trade events Clinical Trial Supply Europe and Temperature Controlled Logistics.

Both events marked an opportunity for Intelsius to launch their highly-awaited products, including the BioTherm Extreme 6, ORCA S, as well as the innovative ORCA 55L, now providing over 120 hours of superior thermal protection for 2-8°C, 15-25°C, 20-24°C, -20°C payloads, in addition to deep-frozen temperature cargo.

The new products are part of Intelsius’ ORCA and BioTherm Extreme ranges, respectively, both specifically designed with patient safety and integrity in mind to ensure “life’s most precious cargo” is always protected.

The first of Intelsius’ London trade events visits, Clinical Trial Supply Europe, ran for three days from 23-25 January at the Victoria Park Plaza Hotel. Joined by several other key pharma industry professionals, Intelsius’ representatives were on hand to participate in the event’s key focal point of discussion; the management of the supply chain and the reduction of wastage.

The second meet at Temperature Controlled Logistics united over 500 industry leaders at London’s ExCel from 30 January to 2 February. Featuring a schedule of successful operation in emerging markets, remaining regulation-compliant ready, and reducing supply chain risks, the ORCA 55L became a timely launch, particularly with its universal pack out, making the product easy to use without trouble or error.

Following both visits, Global Sales Director Lisa Karabedian commented: “It was a pleasure to see our latest ranges and innovations receive such a warm and welcome response from fellow industry delegates. We also enjoyed the opportunity to meet with existing customers and prospective clients to discuss their needs.

“The emphasis on forecasting new ideas in temperature-controlled logistics allowed us to grasp industry demands up close, and Intelsius will continue to develop its products with these requirements in mind.”

For more on our services, visit our homepage here:

Twitter Icon Share on linkedin